News & Views
Addition of CRO Builds Cancer Model Network Support
Jan 10 2021
Pharmatest, a contract research organisation providing clinically predictive preclinical efficacy services for oncology and skeletal diseases, has joined the global network of Repositive’s directory of preclinical cancer models.
“At Repositive, we are committed to establishing new partnerships with specialist CROs to further enhance and strengthen our world-class offering of preclinical cancer models to biopharmaceutical researchers worldwide," said Fiona Nielsen, CEO of Repositive. "Our collaboration with Pharmatest will enable us to do just that,” she added.
"We chose to partner with Repositive because of their ground-breaking, compelling platform, which helps to connect key players in the preclinical cancer research field," said Dr Jukka Rissanen, CEO of Pharmatest. "At Pharmatest, we have unique expertise in the field of bone metastases that we want to be able to share as widely as possible and collaborating with Repositive seems like a great way to do this."
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan
Nov 27 2024 Istanbul, Turkey
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK